Ampersand makes offer for AcCell product line:
This article was originally published in Clinica
Ampersand Medical has offered to buy AccuMed International's AcCell product line, including intellectual property and AccuMed's contracted customer base, for cash, royalties and a licence back for certain AccuMed technology. The AcCell system is a range of automated computer-assisted microscopy work-stations and software that are integrated with lab information systems for the screening and diagnosis of cervical Pap smears and cytology specimens. Chicago-based Ampersand wishes to integrate aspects of the system into its bio-molecular diagnostic systems.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.